Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew P Goetz

Showing results (101-110 of 265) with videos related to

Pageof 27
Sort By:
Pharmacogenomics|October 4, 2011
SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifenAnn M Moyer, Vera J Suman, Richard M Weinshilboum, et al.
The Oncologist|September 22, 2011
Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence scoreArif H Kamal, Charles L Loprinzi, Carol Reynolds, et al.
NPJ Breast Cancer|January 25, 2019
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancerStephen Johnston, Miguel Martin, Angelo Di Leo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancerMatthew P Goetz, David Toft, Joel Reid, et al.
Journal of the American Medical Informatics Association : JAMIA|December 6, 2011
Automated discovery of drug treatment patterns for endocrine therapy of breast cancer within an electronic medical recordGuergana K Savova, Janet E Olson, Sean P Murphy, et al.
Breast Cancer Research and Treatment|January 21, 2018
Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)Jame Abraham, Humberto Caldera, Robert Coleman, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2024
OmicsFootPrint: a framework to integrate and interpret multi-omics data using circular images and deep neural networksXiaojia Tang, Naresh Prodduturi, Kevin J Thompson, et al.
Breast Cancer Research and Treatment|July 4, 2021
A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapyMei-Yin C Polley, Maura N Dickler, Jason Sinnwell, et al.
Nucleic Acids Research|October 24, 2024
OmicsFootPrint: a framework to integrate and interpret multi-omics data using circular images and deep neural networksXiaojia Tang, Naresh Prodduturi, Kevin J Thompson, et al.
Plos One|February 6, 2013
Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogensJohn R Hawse, Malayannan Subramaniam, Muzaffer Cicek, et al.
Pageof 27

Showing results (101-110 of 265) with videos related to

Sort By:
Pageof 27
Pharmacogenomics|October 4, 2011
SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifenAnn M Moyer, Vera J Suman, Richard M Weinshilboum, et al.
The Oncologist|September 22, 2011
Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence scoreArif H Kamal, Charles L Loprinzi, Carol Reynolds, et al.
NPJ Breast Cancer|January 25, 2019
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancerStephen Johnston, Miguel Martin, Angelo Di Leo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancerMatthew P Goetz, David Toft, Joel Reid, et al.
Journal of the American Medical Informatics Association : JAMIA|December 6, 2011
Automated discovery of drug treatment patterns for endocrine therapy of breast cancer within an electronic medical recordGuergana K Savova, Janet E Olson, Sean P Murphy, et al.
Breast Cancer Research and Treatment|January 21, 2018
Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)Jame Abraham, Humberto Caldera, Robert Coleman, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2024
OmicsFootPrint: a framework to integrate and interpret multi-omics data using circular images and deep neural networksXiaojia Tang, Naresh Prodduturi, Kevin J Thompson, et al.
Breast Cancer Research and Treatment|July 4, 2021
A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapyMei-Yin C Polley, Maura N Dickler, Jason Sinnwell, et al.
Nucleic Acids Research|October 24, 2024
OmicsFootPrint: a framework to integrate and interpret multi-omics data using circular images and deep neural networksXiaojia Tang, Naresh Prodduturi, Kevin J Thompson, et al.
Plos One|February 6, 2013
Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogensJohn R Hawse, Malayannan Subramaniam, Muzaffer Cicek, et al.
Pageof 27